A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

NCT07723248 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: Rinzimetostat
DRUG: Darolutamide
DRUG: Enzalutamide
DRUG: Docetaxel

Sponsor

ORIC Pharmaceuticals

Collaborators

[object Object]